Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Novasep Custom Manufacturing Site Passes Fifth Consecutive FDA Inspection Without 483s


LYON, France, August 27, 2018 /PRNewswire/ --

Novasep's robust quality assurance system, fully compliant with the highest world standards, showcased during successful FDA inspection of the Chasse-sur-Rhône (France) facility 

Novasep, a leading supplier of services and technologies for the life sciences industry, is proud to announce that its API development and manufacturing site in Chasse-sur-Rhône, France, has been successfully inspected by the US Food and Drug Administration (FDA).

The on-site inspection, carried out from June 18th to 22nd 2018, confirmed Novasep's compliance with US pharmaceutical cGMP. Novasep's Chasse-sur-Rhône site has an excellent FDA track record with the five last inspections free of any Form 483s. This continues a series of successful FDA inspections at Novasep's CDMO sites. The Le Mans, Mourenx (France) and Leverkusen (Germany) sites also passed their latest FDA inspections without any 483s.

"I'm delighted with the excellent results of the last FDA inspections: it confirms Novasep's continuous commitment to ensuring the highest quality standards for our global customers," said Dr Michel Spagnol, Chairman and CEO of Novasep.

Since the beginning of 2018, Novasep also completed successful local health authorities' inspections for both small molecules and biomolecules custom manufacturing sites: at Le Mans, France, in March 2018, by the ANSM (French National Agency for Medicines and Health Products Safety), and at Gosselies, Belgium, by the FAMHP (Federal Agency for Medicines and Health Products) in June 2018.

 "These results reward the day-to-day involvement of each of our co-workers," said Jean Bléhaut, President of Novasep's Manufacturing Solutions Business Unit, "I would like to congratulate this teamwork, which enables Novasep to provide best-in-class CDMO services for both synthetic APIs and biologics."

Novasep's site in Chasse-sur-Rhône, France, produces APIs and advanced intermediates, mainly for late phase and commercial supply. The site recently commissioned significant expansions of its pilot plant and large scale cryogenic capacities.

For press information, click here: https://www.novasep.com/press-release-about-novasep.html

SOURCE Novasep


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: